Workflow
Will NVO's U.S. Price Cuts Boost Access & Revive Semaglutide Demand?
诺和诺德诺和诺德(US:NVO) ZACKS·2025-11-24 22:31

Key Takeaways Novo Nordisk unveiled limited-time 199pricingfornewWegovyandOzempicself−paypatients.PricingshiftsfollowanagreementtoexpandU.S.accessandmovepatientstowardFDA−approvedtreatments.NovoNordiskseekstoregainsharefromLillyascompoundedproductspressuredemandandguidancecuts.Lastweek,NovoNordisk(NVO)announcedthatitspopularsemaglutide−basedGLP−1injections,Wegovy(forobesity)andOzempic(fordiabetes),willbeofferedatalimited−timepriceof199 pricing for new Wegovy and Ozempic self-pay patients.Pricing shifts follow an agreement to expand U.S. access and move patients toward FDA-approved treatments.Novo Nordisk seeks to regain share from Lilly as compounded products pressure demand and guidance cuts.Last week, Novo Nordisk (NVO) announced that its popular semaglutide-based GLP-1 injections, Wegovy (for obesity) and Ozempic (for diabetes), will be offered at a limited-time price of 199 per m ...